newsfilter
← Latest News
ACCESS Newswire·

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. , a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of